Drug Discovery World

SEPTEMBER 25, 2024

Getting new targets for ADCs is a high priority as it could lead to therapies that are more likely to hit cancer cells, allowing for higher doses and greater efficacy with fewer trade-offs needed to ensure an acceptable safety profile.

Therapies 162

Therapies Pharma Companies FDA Approval FDA 162

Drug Discovery World

NOVEMBER 30, 2023

This presentation covered three primary drivers for a protein expression model: speed, cost and sustainability. “It CAR T cell therapies and in vivo solutions Thomas attended a presentation by Chad May, CSO of Serotiny, called: ‘Improving cell therapies with high-throughput CAR libraries’, in the session relating to optimising CARs.

Protein Expression 147

Protein Expression Engineering DNA Therapies 147

Drug Discovery World

NOVEMBER 9, 2023

Klaus Wagenbauer, PhD, Founder & CEO, Plectonic, on: ‘Programmable DNA-origami-based T cell engagers: PTE’. These include: Samantha Bailey-Bucktrout, PhD, Senior Vice President, Akamis Bio, on: ‘Tumour specific immunogene therapy to deliver protein therapeutics to solid tumour microenvironments’.

Engineering 130

Engineering Therapies Protein Production Science 130

Drug Discovery World

NOVEMBER 13, 2023

Novel/alternative ML-enabled screening technologies for higher POS Following chairperson’s remarks from M Frank Erasmus, PhD, Head, Bioinformatics, Specifica, there will be four presentations and a panel discussion. Jürgen Kuball, PhD, Head, Hematology, University Medical Center Utrecht, on: ‘gdT cell inspired therapies’.

Engineering 147

Engineering Science Bioinformatics Vaccine 147